Literature DB >> 10948339

Expression and prognostic value of the standard CD44 protein in pulmonary adenocarcinoma.

I Takanami1, K Takeuchi, M Naruke.   

Abstract

We examined immunohistochemically the expression of the standard form of CD44 (CD44S) tissue specimens from 164 patients with pulmonary adenocarcinoma. Of the 164 specimens, 79 (48%) expressed CD44S and the incidence of expression correlated with the tumor size. The prognosis for CD44S positive patients was poorer than that of CD44S negative patients. Our findings suggest that CD44S plays an important role in tumor progression and that CD44S expression is a useful prognostic marker for pulmonary adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948339     DOI: 10.3892/or.7.5.1065

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis.

Authors:  Hao Jiang; Wei Zhao; Wei Shao
Journal:  Tumour Biol       Date:  2014-06-07

2.  EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.

Authors:  Yi Shao; Hui Lv; Dian-Sheng Zhong; Qing-Hua Zhou
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

3.  Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.

Authors:  Elaine Lai-Han Leung; Ronald R Fiscus; James W Tung; Vicky Pui-Chi Tin; Lik Cheung Cheng; Alan Dart-Loon Sihoe; Louis M Fink; Yupo Ma; Maria Pik Wong
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

4.  The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression.

Authors:  Saroj K Basak; Mysore S Veena; Scott Oh; Chi Lai; Sitaram Vangala; David Elashoff; Michael C Fishbein; Sanjai Sharma; Nagesh P Rao; Dinesh Rao; Ryan Phan; Eri S Srivatsan; Raj K Batra
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.